ResultsIQ

ResultsIQ › Latest results › Fermenta Biotech Limited

Fermenta Biotech Limited Q2 FY27 results press release summary

NSE: FERMENTA · BSE: 506414

Results press release of 5 Nov 2026, summarised by AI from the filing.

Fermenta H1FY27 consolidated revenue ₹261.9 cr, down 7% YoY, with EBITDA down 34% on lower animal nutrition and prior-year one-offs.

Key takeaways

  1. H1 revenue Consolidated revenue ₹261.9 cr, down 7% YoY; EBITDA ₹45.6 cr, down 34% YoY; PAT ₹18.9 cr, down 52% YoY.
  2. Capacity timeline VITADEE Green® capacities should be available from Q2FY28; Calcifediol expected ready for regulatory approvals by end of FY27.
  3. India share India rose to 51% of consolidated revenue in H1FY27 from 40% a year earlier.
  4. Human Nutrition Human Nutrition revenue grew 2% despite volumes down 13% YoY, and is now close to two-thirds of revenue.
  5. Animal Nutrition Animal nutrition volumes down 31% and average realisation down 35% YoY; sales volumes not pursued at low prices.

Original filing on BSE

Fermenta Biotech Limited Q2 FY27 results

As filed: Revenue ₹117 cr, EBITDA ₹24.1 cr, PAT ₹14.0 cr, EBITDA margin 20.6%.

Not scored. No result for the same quarter last year.

Earlier results and the share price after them

  • Q1 FY27: Revenue ₹112 cr, EBITDA ₹23.0 cr, PAT ₹15.0 cr, EBITDA margin 20.6%. Not scored. No result for the same quarter last year. Share price after the results: −11.7% in 30 days (Nifty 500: −3.3%).

Past price moves after results do not indicate future moves. Not a recommendation.

Fermenta Biotech Limited earnings call, investor presentation and press release summaries

Figures from the company's filings with NSE and BSE. Not investment advice.